Newsroom

Our central location for research news and other stories of related information can be found here.

Monday, April 16, 2012

ACC: Novel therapy lowers LDL-C by 72%

A novel monoclonal antibody lowered low density lipoprotein cholesterol (LDL-C) up to 72 percent in patients with primary hypercholesterolemia in a randomized, double-blind, placebo-controlled trial. The results were announced March 26 at the American College of Cardiology’s 61st scientific session and simultaneously published online in the Journal of the American College of Cardiology.

“This was a very sophisticated trial that gleaned a lot of information,” said co-author Dean J. Kereiakes, MD, medical director of The Christ Hospital Heart and Vascular Center in Cincinnati, in an interview. The study was designed to test the safety and efficacy of the human monoclonal antibody SAR236553/REGN727.

Read the Full Article. (Click Here)

Watch the Video. (Click Here)

No comments:

Post a Comment